Anonymous ID: 7143fa Jan. 21, 2022, 5:47 a.m. No.15428372   🗄️.is 🔗kun   >>8379 >>8382 >>8396 >>8657 >>8660 >>8945 >>9012

>>15428311

stealin it

 

>>15428239

baker

Monash whitepaper notable stems from University of Rhode Island cancelling General Flynn notable.

Turns out new president recommending the cancelling comes from Monash University. At Monash expanded connection to China and took grant money from NIH USG. Swamp is deep.

 

lb below

recommended replacing:

>>15428127, >>15428105 Monash white paper on Gain of Function Research from 2013

 

with these, or just adding:

>>15427364 pb Gen Flynn Massive Corruption will be exposed in the next 24 Hours

>>15427995 University of Rhode Island looking to cancel Gen Flynn, doesn't cancel Fake News

>>15428087 New URI president Marc Parlange expanded CCP connections at Monash University

>>15428105 Monash - Wuhan Institute of Virology collaboration

>>15428127 Monash report funded by US Government on Gain of Function research

Anonymous ID: 7143fa Jan. 21, 2022, 5:53 a.m. No.15428396   🗄️.is 🔗kun   >>8399 >>8605 >>8657 >>8660 >>8773 >>9012

>>15428372

NIH Grants to Monash picrel

> https://reporter.nih.gov/search/jVElONikjUWIeyqPdrp06w/projects

 

> https://research.monash.edu/en/persons/jian-li

 

Personal profile

Biography

 

Professor Jian Li(PhD 2002) is an elected Fellow of the American Academy of Microbiology and Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University.He is a Web of Science Highly Cited Researcher in Pharmacology & Toxicology (2015 - 2017). Dr Li has an internationally recognised track record in the pharmacology of polymyxins and the discovery of novel, safer antimicrobial peptides. He has 389 publications (including 301 on polymyxins alone) with 22,603 citations and an h-index of 74. His team has developed a novel lipopeptide drug QPX9003 from concept into the clinic to target MDR Gram-negative pathogens (NIH/NIAID) and Phase-I clinical trials are conducted in the USA. The majority of modern polymyxin pharmacology data are reported by his group. His research has led to the first dosing guidelines of polymyxins which have been adopted worldwide and have significantly improved clinical practice. Dr Li's research is funded by the NIH, NHMRC, ARC,pharmaceutical companiesand other grant bodies. Dr Li is an Editor of the International Journal of Antimicrobial Agents and an Associate Editor of BMC Microbiology and Frontiers in Microbiology. He is an invited reviewer for 184 international journals and grant/fellowship applications for the Australian National Health and Medical Research Council (NHMRC), Australian Research Council (ARC) and21 international funding bodies (e.g. NIH/NIAID). Dr Li has received numerous awards, including Australian Leadership Award (2013), Australian National Health and Medical Research Council’s Ten of the Best Research Projects (2014) and Australian Academy of Science Jacques Miller Medal (2017).

Monash teaching commitment

 

Supervisor of PhD, Masters and Honours students

Research interests

 

Antibiotics are a cornerstone of modern medicine and over the last century have significantly decreased mortality worldwide. Unfortunately, resistance to these ‘magic bullets’ has become one of the greatest threats to human health that the world faces, now and in the coming decades. If proactive solutions are not found to prevent widespread antibiotic resistance, it is estimated that by 2050 ~10 million people per year will die of infections. The World Health Organization (WHO) has urged all government sectors and society to act on antimicrobial resistance (AMR). In 2017, multidrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii were identified by WHO as the highest priority pathogens, which require urgent attention for the discovery of novel antibiotics. Over the last decade, ‘old’ polymyxins are increasingly used as the last defence against these Gram-negative ‘superbugs’ and unfortunately, resistance to polymyxins has been increasingly reported. As no new antibiotics will be available for Gram-negative ‘superbugs’ in the near future, it is crucial to optimise the clinical use of current antibiotics and develop novel therapies.

Expertise related to UN Sustainable Development Goals

 

In 2015, UN member states agreed to 17 globalSustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

 

>>15428379

>Thanks anon. got it

o7